Adaptive Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (LARTIA Trial) (LARTIA)
Non-Small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Non-Small Cell Lung Cancer focused on measuring Adaptive radiotherapy
Eligibility Criteria
Inclusion Criteria:
- histologically or cytologically proven NSCLC;
- inoperable stage IIIA/IIIB disease and intrathoracic relapse after surgery;
- positron emission tomography (PET)/computed tomography (CT) and/or total-body CT with contrast excluding metastatic disease (including brain);
- no previous radiotherapy treatment;
- Eastern Cooperative Oncology Group performance status of 0 to 1;
- clinically measurable/evaluable disease;
- minimum life expectancy of 12 weeks;
- adequate respiratory, renal, hepatic and bone marrow function and non-contraindicative cardiovascular disease.
Exclusion Criteria:
- previous radiotherapy treatment
- concurrent systemic disorders incompatible with chemotherapy or radiotherapy
Sites / Locations
- Michele Fiore
Arms of the Study
Arm 1
Experimental
Radiotherapy Group
Patients with LA NSCLC treated with concurrent chemoradiation will be enrolled. During treatment all patients will undergo weekly chest CT simulations without intravenous contrast to assess acute toxicity and tumor shrinkage, and they will be all visualized by two radiation oncologists independently. For all CT simulations, each physician will be able to judge whether reduction will be (1) present and clinically significant, (2) present and clinically non significant, or (3) absent. In the case of physician agreement for the first category, a contrast-enhanced CT will be performed to better visualize node reduction, a new target volume will be delineated, and a new treatment plan (replanning study) performed. Patients will be treated without any time break.